InventisBio (SH:688382) Xin Lang Cai Jing·2025-09-12 06:30Group 1 - The core viewpoint of the news is that Yifang Biotechnology has seen a significant increase in its stock price, rising by 5.03% to 36.99 CNY per share, with a trading volume of 388 million CNY and a turnover rate of 2.58%, resulting in a total market capitalization of 21.392 billion CNY [1] - Yifang Biotechnology, established on January 11, 2013, and listed on July 25, 2022, is primarily engaged in the research, production, and sales of innovative drugs, with 100% of its main business revenue coming from technology licensing and cooperation [1] Group 2 - From the perspective of fund holdings, one fund under Nuoan Fund has heavily invested in Yifang Biotechnology, specifically the Nuoan Selected Value Mixed A fund, which increased its holdings by 225,100 shares in the second quarter, bringing its total to 654,100 shares, accounting for 5.97% of the fund's net value, making it the seventh-largest holding [2] - The Nuoan Selected Value Mixed A fund, established on February 28, 2019, has a latest scale of 74.2367 million CNY, with a year-to-date return of 99.47% and a one-year return of 105.15%, ranking 58 out of 8,174 and 392 out of 7,981 respectively [2] - The fund manager, Tang Chen, has been in position for 2 years and 268 days, managing assets totaling 753 million CNY, with the best fund return during his tenure being 105.54% and the worst being 8.84% [2]